Savara (SVRA) Share-based Compensation (2010 - 2026)
Savara (SVRA) posted quarterly Share-based Compensation of $22.5 million for Q1 2026, up 657.07% year-over-year from $3.0 million in Q1 2025, and up 320.17% quarter-over-quarter from $5.4 million in Q4 2025.
Savara (SVRA) Share-based Compensation (2010 - 2026) Analysis & Trends
Savara (SVRA) has reported Share-based Compensation for 17 consecutive years, with $22.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Share-based Compensation rose 657.07% year-over-year to $22.5 million; the TTM figure through Mar 2026 stood at $22.5 million (up 112.77% YoY), while the FY2025 annual figure was $14.4 million, up 23.26% from the prior year.
- Share-based Compensation improved to $22.5 million in Q1 2026 per SVRA's latest filing, from $5.4 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $22.5 million in Q1 2026 and bottomed at $450000.0 in Q3 2022.
- Historically, Share-based Compensation has averaged $3.7 million across 5 years, with a median of $2.2 million in 2024.
- Annual changes were most pronounced in 2022 — Share-based Compensation tumbled 40.86% — and 2026, when it jumped 657.07%.
- Savara's Share-based Compensation stood at $561000.0 in 2022, then surged by 142.6% to $1.4 million in 2023, then soared by 123.07% to $3.0 million in 2024, then surged by 76.38% to $5.4 million in 2025, then soared by 320.17% to $22.5 million in 2026.
- Business Quant data shows SVRA's Share-based Compensation at $22.5 million in Q1 2026, $5.4 million in Q4 2025, and $14.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | Savara | 1.11 Bn | 1.11 Bn | - | 7.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.77 Mn |
| Jun 30, 2026 | 7.77 Mn |
| Mar 31, 2026 | 22.50 Mn |
| Mar 31, 2026 | 22.50 Mn |
| Dec 31, 2025 | 5.36 Mn |
| Dec 31, 2025 | 5.36 Mn |
| Sep 30, 2025 | 14.10 Mn |
| Sep 30, 2025 | 14.10 Mn |
| Jun 30, 2025 | 2.67 Mn |
| Jun 30, 2025 | 2.67 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Mar 31, 2025 | 2.97 Mn |
| Dec 31, 2024 | 3.04 Mn |
| Dec 31, 2024 | 3.04 Mn |
| Sep 30, 2024 | 2.37 Mn |
| Sep 30, 2024 | 2.37 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Jun 30, 2024 | 2.20 Mn |
| Mar 31, 2024 | 2.26 Mn |
| Mar 31, 2024 | 2.26 Mn |